Searchable abstracts of presentations at key conferences in endocrinology

ea0039ep58 | Diabetes | BSPED2015

Acute hyperglycaemia in cystic fibrosis related diabetes: the role of insulin pumps

Drew Samantha , Margetts Rebecca , Gordon Hannah , Peters Catherine

Cystic fibrosis related diabetes (CFRD) is the commonest co-morbidity in CF leading to increased mortality rates. The pathophysiology includes pancreatic fibrosis, reduction in α and ß-cell mass, delayed insulin secretion and variable insulin insensitivity. Insulin production can fluctuate with progression over time to an insulinopenic state. We report two cases of young people with CFRD with high insulin requirements, poor glycaemic control and improvement with the ...

ea0033p39 | (1) | BSPED2013

Extreme hyperlipidaemia with poor glycaemic control in type 1 diabetes

Drew Samantha , Margetts Rebecca , Amin Rakesh , Hindmarsh Peter , Banerjee Kausik , Peters Catherine

Background: Poorly controlled diabetes is associated with dyslipidaemia including high cholesterol and LDL concentrations. This increases the long term risk of atherosclerosis and cardiovascular complications. In children and young people with type 1 diabetes, management with lipid lowering agents is controversial and to date long term evidence of benefit is limited. We report a case of severe dyslipidaemia and the impact of improvement in glycaemic control.<p class="abste...

ea0039p4 | (1) | BSPED2015

Use of long acting somatostatin analogue (Lanreotide) in CHI – its pharmacokinetics and long-term follow-up study

Shah Pratik , Rahman Sofia , McElroy Sharon , Gilbert Clare , Morgan Kate , Hinchey Louise , Button Roberta , Margetts Rebecca , Senniappan Senthil , Guemes Maria , Levy Hannah , Morte Marti Carles , Celma Lezcano Carles , Amin Rakesh , Hussain Khalid

Background: CHI is a cause of severe hypoglycaemia in children. Diazoxide (KATP channel agonist) is used as first-line treatment but is known to cause severe hypertrichosis and reduced appetite in children. Diazoxide unresponsive CHI us treated with daily octreotide subcutaneous injections (3–4 times/day).Objective and hypotheses: To evaluate the efficacy, safety and pharmacokinetics of long acting Somatostatin analogue (Lanreotide) thera...